The German Cancer Research Center (DKFZ) is the largest biomedical research institution in Germany. It has a staff of nearly 3000 members. The HI-STEM lab is located within the DKFZ's main building. DKFZ serves as one of the two shareholders of HI-STEM. Since all members of HI-STEM are also affiliated with the DKFZ, a multitude ofcollaborations are active with other groups at the DKFZ.

The National Center for Tumor Diseases (NCT) in Heidelberg combines patient care and patient-oriented research under one roof. It is jointly run by the DKFZ and the Heidelberg University Hospital (UKHD)to provide best patient care and to carry out clinical research.

Within the German Cancer Consortium (DKTK), cancer researchers and physicians collaborate closely at eight locations across Germany to speed up the transfer to clinical practice of successful cancer research. HI-STEM is involved in several projects funded by the DKTK

Heidelberg University Hospital is one of the leading medical centers in Europe and it is the premium partner of HI-STEM for translational research. (Image source: UniversitätsKlinikum Heidelberg)

HI-STEM is member of the BioRN Cluster, a life science research and industry cluster dedicated to the development of cell-specific, molecular and personalised innovative treatments and to the promotion of the region into one of the leading life science clusters in Europe.

HI-STEM is part of HeLeNe - The Heidelberg Leukemia Network.

Within HeLeNe, short for Heidelberg Leukemia Network, over 20 research groups have teamed up as a grass root initiative aiming to bring together the broad expertise in the Heidelberg area on treatment of and research of those disease in order to improve progress leading to improved treatment options for patients.

Andreas Trumpp is a member of the executive board of the German Stem Cell Network (GSCN e.V.)

The Sonderforschungsbereich 873 (Collaborative Research Center) "Maintenance and Differentiation of Stem Cells in Development and Disease" has been funded by the Deutsche Forschungsgemeinschaft (DFG) since July 1, 2010. Prof. Dr. Jan U. Lohmann (Heidelberg University, COS) serves as Spokesperson.

Marieke Essers, Mick Milsom and Andreas Trumpp are project leaders in the SFB, Andreas Trumpp also serves as Vice-Spokesperson.

The DKFZ-ZMBH-Alliance is a strategic alliance of the Research Program Cell and Tumor Biology of the German Cancer Research Center (DKFZ) and the Center for Molecular Biology of the Ruprecht-Karls-University of Heidelberg (ZMBH) with a main focus on basic research in the area of molecular life sciences. This concept combines advantages of both institutions and creates a particularly attractive research environment.

Since 2016, Andreas Trumpp is co-director of the DKFZ-ZMBH Alliance.

At Genavinta Health, we combine the power of AI-driven genomics and precision medicine to transform how cancer care is delivered worldwide. Based out of Heidelberg a global hub of innovation, research, and Nobel prize-winning discoveries. We are dedicated to creating personalized healthcare solutions that address cancer’s complexity. Each patient’s cancer is unique, shaped by genetics, biology, and environment. By analyzing vast genomic data with advanced AI technology, we uncover insights that enable doctors to deliver treatments tailored to the individual needs of every patient. Our mission is: - To revolutionize healthcare through AI-powered genomic tools. - To turn complex genetic data into actionable clinical decisions. - To make precision medicine accessible, affordable, and actionable for patients globally. Driven by expertise and supported by a multidisciplinary team of scientists, clinicians, and industry leaders, we bridge the gap between groundbreaking discoveries and real-world patient care. At Genavinta, we believe in smarter medicine for healthier lives. Follow us to stay updated on how we’re driving innovation, collaboration, and tangible impact in precision cancer care.